Advancing Precision Psychiatry: Insights from the Neuropsychiatry Congress
Event recap: German Society for Biological Psychiatry and the Working Group for Neuropsychopharmacology and Pharmacopsychiatry
At this year’s joint congress of the German Society for Biological Psychiatry and the Working Group for Neuropsychopharmacology and Pharmacopsychiatry in Berlin, a clear message emerged: the future of mental health research lies in moving beyond symptom-based classifications toward a more integrated, biology-driven understanding of disease.
Speakers highlighted the growing convergence of environmental, biological, and psychological factors in shaping neuropsychiatric conditions. At the same time, the limitations of current diagnostic frameworks—largely based on overlapping clinical symptoms—are becoming increasingly evident. A shift toward transdiagnostic and dimensional models is underway, supported by large-scale datasets that reveal shared mechanisms across disorders.
A central theme, strongly emphasized by Professor Marion Leboyer (Professor of Psychiatry, Université Paris Est Créteil, Dir Fondation FondaMenta), was the urgent need to advance precision psychiatry. Key unmet needs include the identification of biomarkers that can:
- Stratify patients into more homogeneous subgroups
- Provide objective measures of therapeutic efficacy in clinical trials
- Enable the development of mechanism-based therapies
Addressing these challenges requires deep phenotyping and multi-modal biomarker approaches, moving beyond a narrow focus on key inflammatory markers toward a broader, pathway-level view of disease biology.
Insights into proteomic associations across neuropsychiatric conditions from the UK Biobank
Olink has a long-standing commitment to supporting precision medicine through high-quality proteomics, supporting researchers across the biomarker continuum – from discovery to clinical translation. This is exemplified by its role in large-scale initiatives such as the UK Biobank Pharma Proteomics Project, data from which were presented at the congress.
About the video: Boxi Zhang, Data Scientist at Olink, part of Thermo Fisher Scientific, presents insights from pathways-level analysis of proteomic associations across neuropsychiatric conditions from the UK Biobank dataset generated through the Olink Explore platform.
View the poster here.
The UK Biobank Pharma Proteomics Project provides a large-scale resource for studying links between circulating proteins, genetics, and disease risk. Plasma proteomic data from UK Biobank has previously been used to identify associations with genetic variation and incident disease. In this analysis, the focus was on proteomic associations across selected neuropsychiatric conditions, aiming to identify proteins linked to future disease risk, compare shared and disease-specific patterns, and highlight candidate biomarkers relevant to neurodegeneration, neurological dysfunction, psychiatric disease, and addiction.
The findings underscore both the complexity and the opportunity within neuropsychiatric research. Proteomic association patterns vary substantially across conditions, while also revealing meaningful overlap. Shared protein signals point to common biological mechanisms, whereas disease-specific profiles highlight distinct pathophysiology. Pathway-level analysis further strengthens these insights, connecting broad biological processes to more precise mechanistic pathways.
Together, this work provides a valuable framework for prioritizing candidate biomarkers and guiding downstream validation—bringing the field one step closer to actionable precision psychiatry.
Interested in exploring precision neurology further?
Dive deeper into UK Biobank–derived insights into neurological disorders, watch our webinar on circulating inflammatory biomarkers in cognitive function and dementia, or explore additional articles, videos, and resources on our spotlight page.